Akt blocks the tumor suppressor activity of LKB1 by promoting phosphorylation-dependent nuclear retention through 14-3-3 proteins

American Journal of Translational Research

Volumn 4, Issue 2, 2012, Pages 175-186

  Liu, Ling ^a   Siu, Fung Ming ^b   Che, Chi Ming ^b   Xu, Aimin ^a   Wang, Yu ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

14 3 3; Akt kinase; LKB1; Nuclear cytoplasmic shuttling; Tumorigenesis

Indexed keywords

ADAPTOR PROTEIN; MUTANT PROTEIN; PROTEIN 14 3 3; PROTEIN KINASE B; PROTEIN KINASE LKB1; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INHIBITION; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; WILD TYPE;

EID: 84860178975     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A and Aaltonen LA. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-187.
2. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W and Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18: 38-43.
3. Williams T, Brenman JE. LKB1 and AMPK in cell polarity and division. Trends Cell Biol 2008; 18: 193-198.
4. Spicer J, Ashworth A. LKB1 kinase: master and commander of metabolism and polarity. Curr Biol 2004; 14: R383-385.
5. Jansen M, Ten Klooster JP, Offerhaus GJ and Clevers H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 2009; 89: 777-798.
6. Tiainen M, Ylikorkala A and Makela TP. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA 1999; 96: 9248-9251.
7. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M and Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-2008.
8. Alexander A, Walker CL. The role of LKB1 and AMPK in cellular responses to stress and damage. FEBS Lett 2011; 585: 952-957.
9. Alessi DR, Sakamoto K and Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75: 137-163.
10. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC and Alessi DR. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 2003; 22: 5102-5114.
11. Tiainen M, Vaahtomeri K, Ylikorkala A and Makela TP. Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet 2002; 11: 1497-1504.
12. Sapkota GP, Boudeau J, Deak M, Kieloch A, Morrice N and Alessi DR. Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J 2002; 362: 481-490.
13. [Xie Z, Dong Y, Scholz R, Neumann D and Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metforminenhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008; 117: 952-962.
14. Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, Alessi DR and Clevers HC. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 2003; 22: 3062-3072.
15. Boudeau J, Scott JW, Resta N, Deak M, Kieloch A, Komander D, Hardie DG, Prescott AR, van Aalten DM and Alessi DR. Analysis of the LKB1-STRAD-MO25 complex. J Cell Sci 2004; 117: 6365-6375.
16. Dorfman J, Macara IG. STRADalpha regulates LKB1 localization by blocking access to importin-alpha, and by association with Crm1 and exportin-7. Mol Biol Cell 2008; 19: 1614-1626.
17. Boudeau J, Kieloch A, Alessi DR, Stella A, Guanti G and Resta N. Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients. Hum Mutat 2003; 21: 172.
18. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, Moon RT, Shepherd PR, Cooper GJ and Wang Y. Adiponectin haploinsufficiency promotes mammary tumor development in MMTVPyVT mice by modulation of phosphatase and tensin homolog activities. PLoS One 2009; 4: e4968.
19. Law IK, Liu L, Xu A, Lam KS, Vanhoutte PM, Che CM, Leung PT and Wang Y. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti-aging and metabolic effects of sirtuins. Proteomics 2009; 9: 2444-2456.
20. Zu Y, Liu L, Lee MY, Xu C, Liang Y, Man RY, Vanhoutte PM and Wang Y. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010; 106: 1384-1393.
21. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ and Xu A. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66: 11462-11470.
22. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003; 3: 931-943.
23. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009; 19: 16-23.
24. Wang B, Yang H, Liu YC, Jelinek T, Zhang L, Ruoslahti E and Fu H. Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 1999; 38: 12499-12504.
25. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464.
26. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010; 2: 19-42.
27. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
28. Hsieh AC, Truitt ML and Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 2011; 105: 329-336.
29. Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE and Ramesh V. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 2009; 15: 1940-1946.
30. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB and Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 2009; 15: 7538-7546.
31. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
32. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271.
33. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ and Powell MB. The hypoxic microenvironment of the skin contributes to Aktmediated melanocyte transformation. Cancer Cell 2005; 8: 443-454.
34. Xie Z, Dong Y, Zhang J, Scholz R, Neumann D and Zou MH. Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. Mol Cell Biol 2009; 29: 3582-3596.
35. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, Dalal SN, DeCaprio JA, Greenberg ME and Yaffe MB. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 2002; 156: 817-828.
36. Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K and Tsuruo T. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 2000; 19: 2652-2661.
37. Yang HY, Wen YY, Chen CH, Lozano G and Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003; 23: 7096-7107.
38. Wang R, Brattain MG. AKT can be activated in the nucleus. Cell Signal 2006; 18: 1722-1731.
39. Liu MY, Cai S, Espejo A, Bedford MT and Walker CL. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res 2002; 62: 6475-6480.
40. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
41. Fujita N, Sato S, Katayama K and Tsuruo T. Aktdependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002; 277: 28706-28713.
42. Jimenez AI, Fernandez P, Dominguez O, Dopazo A and Sanchez-Cespedes M. Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway. Cancer Res 2003; 63: 1382-1388.